Curaleaf Holdings (CURLF) Interest Expenses (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Interest Expenses of $299.0 million for Q4 2025, up 110855.93% year-on-year from N/an in Q4 2024, and up 110855.93% on a QoQ basis from -$270000.0 in Q4 2024.
Curaleaf Holdings (CURLF) Interest Expenses (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Interest Expenses for 7 consecutive years, with $299.0 million the latest figure, recorded in Q4 2025.
- Quarterly Interest Expenses rose 110855.93% year-over-year to $299.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $299.0 million (up 6215.54% YoY) and the FY2025 annual result came in at $586.0 million, up 39.79% from the prior year.
- Interest Expenses grew to $299.0 million in Q4 2025 per CURLF's latest filing, from -$270000.0 in the prior quarter.
- Over the last five years, Interest Expenses for CURLF reached as high as $299.0 million in Q4 2025 and fell as low as -$17.5 million in Q4 2022.
- A 5-year average of $40.0 million and a median of $2.3 million in 2021 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses tumbled 100.36% — and 2025, when it jumped 110855.93%.
- Year by year, Interest Expenses stood at $32.2 million in 2021, then sank by 154.45% to -$17.5 million in 2022, then jumped by 530.58% to $75.4 million in 2023, then slumped by 100.36% to -$270000.0 in 2024, then soared by 110855.93% to $299.0 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $299.0 million, -$270000.0, and $5.0 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 299.04 Mn |
| Dec 31, 2025 | 299.04 Mn |
| Dec 31, 2024 | -270,000.00 |
| Dec 31, 2024 | -270,000.00 |
| Sep 30, 2024 | 5.01 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Dec 31, 2023 | 75.42 Mn |
| Dec 31, 2023 | 75.42 Mn |
| Sep 30, 2023 | 892,000.00 |
| Sep 30, 2023 | 892,000.00 |
| Dec 31, 2022 | -17.52 Mn |
| Dec 31, 2022 | -17.52 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Sep 30, 2021 | 32.17 Mn |
| Sep 30, 2021 | 32.17 Mn |
| Jun 30, 2021 | 937,000.00 |
| Jun 30, 2021 | 937,000.00 |
| Mar 31, 2021 | 332,000.00 |
| Mar 31, 2021 | 332,000.00 |